NDA 213227 · Curium
Detectnet
Copper Cu-64 Dotatate · Intravenous · Radioactive Diagnostic Agent
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Sep 3, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
2 Phase 3, 4 recruiting
FAERS reports
54
5 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 31, 2025.
Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Detectnet is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. ( 1 )
Mechanism: Copper Cu 64 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress SSTR2 receptors. Copper Cu 64 is a positron (β + ) emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 3, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterReviewLabel
1 products under this application
- DETECTNET · COPPER CU-64 DOTATATE 4mL (1mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Copper Cu-64 Dotatate" as an intervention, any sponsor and status, largest first.
- Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine NeoplasmsStatus unknown
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05709171 · 200 participants (planned) · Start Jan 17, 2023 · Primary completion Jan 1, 2025
Drug: 18F-FDG; 64Cu-Dotatate · For: GEP-NET; Neuroendocrine Tumors; Neuroendocrine Carcinoma and 1 more
Sites: Copenhagen, Denmark
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsPivotal-lookingRecruiting
Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
NCT06878664 · 166 participants (planned) · Start Jun 12, 2025 · Primary completion Jan 2029
Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm. and 2 more · For: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
Sites: Caen, France; Dijon, France; Lille, France · 21 sites in all
- Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATEPivotal-lookingCompleted
Radiomedix, Inc.Industry
NCT03673943 · 63 participants · Start Aug 23, 2018 · Primary completion Mar 23, 2019
Drug: 64Cu-DOTATATE · For: Neuroendocrine Tumors
Sites: Houston, Texas
Novartis PharmaceuticalsNovartis (NVS)
NCT06379217 · 31 participants · Start Jul 29, 2024 · Primary completion Oct 16, 2026
Drug: [68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE and 9 more · For: Metastatic Neuroendocrine Prostate Cancer
Sites: Omaha, Nebraska; New York, New York; Nantes, France · 9 sites in all
Emory UniversityAcademic, hospital or other
NCT07150546 · 15 participants (planned) · Start Oct 14, 2025 · Primary completion Sep 30, 2026
Drug: Lutetium Lu 177 Dotatate · For: Digestive System Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1 and 1 more
Sites: Atlanta, Georgia · 2 sites in all
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsActive, not recruiting
Advanced Accelerator ApplicationsNovartis (NVS)
NCT04711135 · 11 participants · Start Aug 31, 2022 · Primary completion Mar 12, 2024
Drug: Lutetium [177Lu] oxodotreotide/dotatate · For: Gastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paraganglioma
Sites: Lexington, Kentucky; Cincinnati, Ohio; Philadelphia, Pennsylvania · 7 sites in all
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT06016855 · 6 participants (planned) · Start May 31, 2024 · Primary completion May 28, 2027
Drug: Lutetium Lu 177 Dotatate; Copper Cu 64 Dotatate · For: Digestive System Neuroendocrine Tumor G1; Digestive System Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm and 3 more
Sites: Nashville, Tennessee
University of Wisconsin, MadisonAcademic, hospital or other
NCT06122610 · 4 participants · Start Mar 7, 2025 · Primary completion May 31, 2026
Drug: 64Cu-Dotatate; 177Lu-Dotatate · For: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor
Sites: Madison, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea22
- flushing13
- chest discomfort8
- radioisotope scan abnormal7
- palpitations6
- abdominal pain5
- chest pain4
- drug ineffective4
- incorrect drug administration rate4
- vomiting4
- dyspnoea3
- hypersensitivity3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 40 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.